Pauling on the Homefront: The Development of Oxypolygelatin, Part 2

Dan Campbell and Linus Pauling in a Caltech laboratory, 1943.

Dan Campbell and Linus Pauling in a Caltech laboratory, 1943.

Science cannot be stopped. Man will gather knowledge no matter what the consequences — and we cannot predict what they will be. Science will go on — whether we are pessimistic, or are optimistic, as I am. I know that great, interesting, and valuable discoveries can be made and will be made…But I know also that still more interesting discoveries will be made that I have not the imagination to describe — and I am awaiting them, full of curiosity and enthusiasm.
Linus Pauling, October 15, 1947.

After developing a promising blood plasma substitute during World War II, Pauling found his funding cut and his contract with the Office of Scientific Research and Defense coming to an end. Rather than abandon the project, the Caltech researchers chose to forge ahead.

Frustrated with the lack of progress, Pauling and his team scraped together enough residual funds to allow for one more series of experiments. Pauling began injecting mice and rabbits with his synthetic plasma, carefully monitoring their health and examining blood samples to determine the effects of the treatment. The results were satisfactory but not enough to put the project back in the good graces of the Committee on Medical Research. Pauling knew that the only way to stimulate interest (and funding) for the project was to prove that his substance could be used in humans. In September of 1944, twelve patients at Los Angeles General Hospital were injected with Oxypolygelatin, all exhibiting favorable reactions. Pauling had the results he needed.

Letter from Linus Pauling to B. O. Raulston, September 19, 1944.

Letter from Linus Pauling to B. O. Raulston, September 19, 1944.

Statement of Work Carried Out Under Contract OEMomr-153, 1944.  Page 1.

Statement of Work Carried Out Under Contract OEMomr-153, 1944. Page 1.

Statement of Work Carried Out Under Contract OEMomr-153, 1944.  Page 2.

Statement of Work Carried Out Under Contract OEMomr-153, 1944. Page 2.

In a final effort to save the project, Pauling submitted one last application, noting the success of his experiments with both animal and human patients. To aid his cause, Pauling attempted to find support at the source, sending individual letters to key members of the CMR.

In October of 1944, the CMR responded to his requests for aid, providing a $10,000, nine-month grant. The CMR had previously assured Pauling that the Committee would arrange any necessary physiological tests that could not be completed at Caltech and, upon the renewal of the Oxypolygelatin contract, they reaffirmed this promise.

While Pauling waited for the CMR to complete arrangements for testing, he and his team continued to refine the production process, ironing out wrinkles that had developed in the course of frantic experimentation. During the early months of the Oxypolygelatin program, Pauling had corresponded often with Robert Loeb, a researcher at the College of Physicians and Surgeons in New York. In a 1943 letter to Loeb he wrote,

It looks as though our method of preparation is not well enough standardized to give a uniform product – the osmotic pressure varies from preparation to preparation. With some evidence from the ultracentrifuge as to how the distribution in molecular weight is changing, we should be able to improve the method.

The lack of uniformity in the substance was a problem for Pauling and his team. In order to locate the irregularities, the researchers needed results from a series of physiological tests. Unfortunately, the CMR had yet to arrange for the promised tests and Pauling’s grant was about to expire.

Letter from Linus Pauling to Robert Loeb, August 17, 1943.

Letter from Linus Pauling to Robert Loeb, August 17, 1943.

By the spring of 1945, Pauling had virtually given up on the project. He had resigned his post as responsible investigator and allowed Campbell to take his place. With the rest of Caltech still knee deep in war research, Pauling had no trouble finding other projects to attract his attention. As a result, his Oxypolygelatin work was relegated to correspondence with gelatin manufacturers and a few curious scientists. In a letter to Chester Keefer of the Committee on Medical Research, Pauling stated,

I feel that the development of Oxypolygelatin has been delayed by a full twelve months by the failure of the CMR to arrange for the physiological testing of the preparation, despite the assurances to me, beginning July 24, 1943, that this testing would be carried out under CMR arrangement. I feel that I myself am also to blame, for having continued to rely upon the CMR, long after it should have been clear to me that the promised action was not being taken and presumably would not be taken.

Letter from Linus Pauling to Chester Keefer, March 12, 1945. Page 1.

Letter from Linus Pauling to Chester Keefer, March 12, 1945. Page 1.

Letter from Linus Pauling to Chester Keefer, March 12, 1945. Page 2.

Letter from Linus Pauling to Chester Keefer, March 12, 1945. Page 2.

Letter from Linus Pauling to Chester Keefer, March 12, 1945. Page 3.

Letter from Linus Pauling to Chester Keefer, March 12, 1945. Page 3.

The project was dead. The CMR had lost interest and no lab in the country was either willing to or capable of performing the tests Pauling required. Even worse for the project, Germany was on the brink of surrender and Japan was losing ground in the Pacific; the war would be over soon and with victory would come the closure of war research programs all over the country.

The team quietly disbanded, each member returning to old projects or starting up fresh lines of research. In 1946, Pauling, Koepfli and Campbell filed for a patent for Oxypolygelatin and its manufacturing process which they immediately transferred to the California Institute Research Foundation.

Oxypolygelatin patent agreement, December 4, 1946.

Oxypoly-gelatin patent agreement, December 4, 1946.

In 1947, the American Association of Blood Banks was founded and in 1948 the American National Red Cross began widespread blood donation campaigns. The genesis of the two programs allowed for large supplies of fresh blood to be dispersed throughout U.S. hospitals on a regular basis, virtually eliminating the need for a plasma substitute during peacetime.

While Pauling was the source of many scientific breakthroughs during his career, in the end Oxypolygelatin was a failed project. Over the following years, he would occasionally discuss his blood plasma work with an interested scientist or mention it at a symposium address, but he never returned to the Oxypolygelatin problem.

For more information on Pauling’s Oxypolygelatin research, read his 1949 project report or view this 1974 letter regarding the development of Oxypolygelatin production in China. For additional Pauling content, visit Linus Pauling: It’s in the Blood! or the Linus Pauling Online portal.

About these ads

3 Responses

  1. Do you know of Pauling’s work for
    The Sectional Research Program for
    Biological Warfare Defense? It would have have from 1952-1953. Pauling did a
    paper on oxypolygelatin. Many well known
    scientists–such as Michael DeBakey,
    Albert Sabin, Jonas Salk , and Hans Selye–
    participated.
    Thanks…j. Morra

  2. J. – thanks for your comment!

    We were able to find a reference to a conference on oxypolygelatin that appears to have been hosted by the National Research Council in 1953, though evidence of Pauling’s involvement seems to be missing from the collection. We can add that in the early 1950s Pauling did participate in the Office of Naval Research’s Protein Substitutes Group as a direct result of his work with oxypolygelatin. He also considered a return to oxypolygelatin research in the early 1970s but ultimately concluded that there wasn’t enough of a need for plasma [volume] expanders to merit the work.

    We can also tell you that Harry W. Bowman published a paper in 1953 entitled “Clinical Evaluation of Dextran as a Plasma Volume Expander” that touched on oxypolygelatin as a potential alternative to dextran and polyvinylpyrrolidone.

    If you’re interested in a more comprehensive look at plasma substitutes like oxypolygelatin, you might find “Modified Gelatins as Plasma Substitutes” (Lundsgaard-Hansen, Hassig, Nitschmann; 1967) of value.

  3. […] our blog posts “Blood and War: The Development of Oxypolygelatin, Part 1,” and “Pauling on the Homefront: The Development of Oxypolygelatin, Part 2.” Today’s post will focus on the patenting, ownership and uses of oxypolygelatin after […]

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 60 other followers

%d bloggers like this: